Article Details

Enhertu significantly improved both progression-free and overall survival in DESTINY ...

Retrieved on: 2022-02-21 07:30:04

Tags for this article:

Click the tags to see associated articles and topics

Enhertu significantly improved both progression-free and overall survival in DESTINY .... View article details on hiswai:

Excerpt

First HER2-low metastatic breast cancer Phase III results for AstraZeneca and Daiichi Sankyo's Enhertu offer potential to redefine how the disease ...

Article found on: pipelinereview.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up